The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Mechanisms Of Interaction And Therapeutic Strategies For Polymicrobial Biofilms
Funder
National Health and Medical Research Council
Funding Amount
$607,231.00
Summary
A public health crisis is brewing with regard to hospital-acquired infections. The ability of bacterial and fungal organisms to attach and bind tightly to the surface of invasive medical devices is the root-cause of the majority of hospital-acquired infections. This research will study how bacteria and fungi interact in communities attached to medical devices, and devise strategies for their combined treatment.
Molecular Basis Of Asymptomatic Colonization Of The Human Urinary Tract
Funder
National Health and Medical Research Council
Funding Amount
$461,894.00
Summary
Urinary tract infections (UTI) are among the most common infectious diseases of humans and a major cause of morbidity and mortality. In the USA, UTI accounts for >$1.6 billion in medical expenses each year. It is estimated that 50% of women will develop a UTI in their lifetime. This research aims to understand the processes by which bacteria colonize the human bladder and the surface of urinary catheters. The work has implications for the development of new approaches to prevent and treat UTI ....Urinary tract infections (UTI) are among the most common infectious diseases of humans and a major cause of morbidity and mortality. In the USA, UTI accounts for >$1.6 billion in medical expenses each year. It is estimated that 50% of women will develop a UTI in their lifetime. This research aims to understand the processes by which bacteria colonize the human bladder and the surface of urinary catheters. The work has implications for the development of new approaches to prevent and treat UTI.Read moreRead less
CSI-Sydney: New Technologies To Treat Chronic Sinus Infection
Funder
National Health and Medical Research Council
Funding Amount
$412,213.00
Summary
Chronic sinus infection (CSI) is prevalent and results in severe discomfort and pain for many Australians; yet amazingly, has no specific cure or effective treatment. Our multi-disciplinary research team and an Australian health and medical research company, (AFT Pharmaceuticals) have partnered to develop a novel device that specifically targets the sinuses and a formulation capable for simultaneously removing mucus, dispersing biofilms and killing bacteria in the nasal cavities.
Innovative Antimicrobial Treatments For Successful Bone Allografts
Funder
National Health and Medical Research Council
Funding Amount
$473,706.00
Summary
Bone healing sites are commonly infected, and this is associated with adverse clinical and significant socioeconomic outcomes. These studies will determine whether our novel antimicrobials can be used to reduce bone infections by studying the combination of antimicrobials and bone in laboratory and bone fracture studies whilst minimising the potential of developing antibiotic resistance.
NOVEL SOLUTIONS FOR ANTIMICROBIAL RESISTANT PATHOGENS
Funder
National Health and Medical Research Council
Funding Amount
$474,513.00
Summary
Antibiotic resistance and infections caused by superbugs are major public health concerns. My fellowship aims to develop new strategies to prevent and treat infections caused by resistant superbugs. I will use innovative approaches both in the laboratory and in the hospital setting, and foster research across multiple groups, to solve “real-life” clinical problems. The proposed work will improve the outcomes for the most vulnerable hospitalised patients.
Urinary Tract E. Coli: The Good Guys Versus The Bad Guys
Funder
National Health and Medical Research Council
Funding Amount
$296,150.00
Summary
Escherichia coli is the primary cause of urinary tract infection (UTI) in the developed world. In Australia alone, E. coli affects more than 250,000 yearly to the extent where they require medical intervention. It is estimated that one in four women and one in twenty men will develop a UTI in their lifetime and in the USA UTIs result in $1.6 billion in medical expenses each year. Uropathogenic E. coli (UPEC) strains readily form biofilms on indwelling catheters and recent evidence suggests that ....Escherichia coli is the primary cause of urinary tract infection (UTI) in the developed world. In Australia alone, E. coli affects more than 250,000 yearly to the extent where they require medical intervention. It is estimated that one in four women and one in twenty men will develop a UTI in their lifetime and in the USA UTIs result in $1.6 billion in medical expenses each year. Uropathogenic E. coli (UPEC) strains readily form biofilms on indwelling catheters and recent evidence suggests that they also form biofilm-like aggregates in the bladder. No treatment other than antibiotics (often inefficient due to resistance) is currently available. E. coli is also the most frequent cause of asymptomatic bacteriuria (ABU). ABU occurs in up to 6% of healthy individuals and affects high risk groups such as the elderly and diabetics. In general, most patients with ABU do not need treatment and in many cases the colonizing organism actually helps to prevent infection by other more virulent bacteria. The aim of this project is to compare UPEC and ABU E. coli for differences associated with virulence and biofilm growth. The project will generate a comprehensive and defined strain bank relative to E. coli that cause UTI. Understanding biofilm growth by this organism may lead to the development of improved and-or novel treatments. Furthermore, increased knowledge of ABU E. coli is essential if we are to fully explore the possibility of employing these organisms as probiotic agents to prevent infection by other pathogens in specific high risk patient groups.Read moreRead less
The Use Of Nitric Oxide To Control Infections By Biofilm Forming Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$551,767.00
Summary
80% of infections are the result of bacteria growing as a biofilm. It can require up to 1000x's the normal antibiotic concentration to kill a biofilm. When the bacteria disperse from the biofilm, they become antibiotic sensitive again. Our team has identified a strategy that controls biofilm dispersal. This project will design and test novel compounds that disperse biofilms so that they can be killed by the host immune response or by antibiotic treatment.
The Development Of Novel, Biofilm-resistant Biomaterials
Funder
National Health and Medical Research Council
Funding Amount
$147,360.00
Summary
Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our tec ....Almost all patients who are catheterised long term develop a bacterial infection. Most often, the infection is the result of colonisation of the catheter surface by bacteria. Bacterial colonisation of the surface of biomedical devices represents a significant health threat as such bacterial biofilms are extremely resistant to traditional antibiotic regimens. This project aims to develop novel materials that prevent bacterial colonisation on catheters and other biomedical related devices. Our technology is based on compounds identified from a marine alga that prevent bacterial colonisation of its surface. Similarly, we have shown that these compounds, when coated onto test surfaces, prevent bacterial colonisation of a range of materials.Read moreRead less
Metabolism-driven Interactions Of Non-typeable Haemophilus Influenzae And Its Host: A Critical Factor In Infection?
Funder
National Health and Medical Research Council
Funding Amount
$474,932.00
Summary
Non-typeable Haemophilus influenzae (NTHi) is the underlying cause of many severe acute and chronic respiratory infections, which represent a significant burden to the healthcare system. As NTHi is unable to survive outside the human host, it is is highly adapted to survival in the body niches it colonizes. We are investigating how NTHI is able to survive in the presence of tissue inflammation, and whether it contributes to the inflammatory process through some of its metabolic products.